Orionis Biosciences Entered into a Multi-Year Collaboration with Genentech to Discover and Develop Molecular Glue Class Medicines
Shots:
- As per the agreement, Orionis will receive $47M up front and is eligible for up to $2B in development & commercial milestones, plus tiered royalties. Genentech received the rights to develop & commercialize small molecule monovalent glue therapies to treat indications incl. oncology & neurodegeneration
- Orionis will be responsible for the discovery & optimization of molecular glues for targets selected by Genentech & Genetech will be responsible for further development activities
- Genentech will develop these therapies using Orionis's Allo-Glue platform that integrates chemical biology technologies for high throughput discovery, rational design & optimization of small molecules that promote/induce interactions of proteins in living cells
Ref: Businesswire | Image: Genentech
Related News:- Novartis Enters into a Four-Year Collaboration with Orionis Biosciences to Tackle Intractable Disease Targets
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
